Biotech Values

[biomaven0]

I disagree on this - the situation is different when there are already approved drugs in the class. Then it requires a determination by the agency that the prospective drug might have better efficacy or safety.

I'd note that GLPG's drug did not get fast track.

Given the likely efficacy of pam is in the same general ballpark as the existing drugs, BTD was always a long shot for this indication. Let's see if it's still on the cards for pancreatic cancer.